After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
But Perspective sinks again.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
The company will acquire ImCheck for €350m.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
